Sun Pharma Advanced Research Co Ltd stock PB Ratio (=5.44) is close to 1-year high of 5.76.
The historical rank and industry rank for Sun Pharma Advanced Research Co's PB Ratio or its related term are showing as below:
NSE:SPARC'
s PB Ratio Range Over the Past 10 Years
Min: 3.02 Med: 32.34 Max: 1639.66
Current: 5.59
During the past 13 years, Sun Pharma Advanced Research Co's highest PB Ratio was 1639.66. The lowest was 3.02. And the median was 32.34.
NSE:SPARC's PB Ratio is ranked worse than 84.69% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs NSE:SPARC: 5.59
During the past 3 years, the average Book Value Per Share Growth Rate was 37.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sun Pharma Advanced Research Co was 180.40% per year. The lowest was -53.30% per year. And the median was 11.90% per year.
Back to Basics: PB Ratio
Sun Pharma Advanced Research Co (NSE:SPARC) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sun Pharma Advanced Research Co PB Ratio Related Terms
Sun Pharma Advanced Research Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sun Pharma Advanced Research Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sun Pharma Advanced Research Co's PB Ratio falls into.
Sun Pharma Advanced Research Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sun Pharma Advanced Research Co (NSE:SPARC) has a PB Ratio of 5.80 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sun Pharma Advanced Research Co and its competitors. This is 82% below median its historical median of 32.34. Over the past decade, Sun Pharma Advanced Research Co's PB Ratio has ranged from 3.02 to 1,639.66. According to the industry distribution chart, Sun Pharma Advanced Research Co ranks #780 out of 921 companies in the Drug Manufacturers industry, placing it in the top 84.7%.
Is Sun Pharma Advanced Research Co's PB Ratio too high?
Sun Pharma Advanced Research Co's current PB Ratio of 5.80 is 82% below median its 10-year median of 32.34. Over the past 10 years, this metric has ranged from a low of 3.02 to a high of 1,639.66. The Drug Manufacturers industry median PB Ratio is 1.91. Sun Pharma Advanced Research Co's value of 5.80 is 203.7% above this industry median. Based on the distribution chart, Sun Pharma Advanced Research Co ranks #780 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sun Pharma Advanced Research Co ranks #780 out of 921 companies for PB Ratio. This places Sun Pharma Advanced Research Co in the lower half of its industry. The industry median PB Ratio is 1.91. Sun Pharma Advanced Research Co's value of 5.80 is 203.7% above this benchmark. Historically, Sun Pharma Advanced Research Co's own PB Ratio has ranged from 3.02 to 1,639.66 over the past decade. While the company's 10-year median is 32.34 vs. the industry median of 1.91, Sun Pharma Advanced Research Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sun Pharma Advanced Research Co's current PB Ratio of 5.80 is 203.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sun Pharma Advanced Research Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sun Pharma Advanced Research Co's current PB Ratio is 5.80, which is 82% below median its own 10-year median of 32.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Possible Value Trap. The stock's GF Value™ is ₹4,504.88, compared to a current price of ₹239.37 — trading 94.7% below its estimated fair value. The current PB Ratio is 5.80, which is 82% below median its 10-year median of 32.34 and 203.7% above the Drug Manufacturers industry median of 1.91. Sun Pharma Advanced Research Co's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current PB Ratio is 5.80 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be undervalued.
The current stock price of ₹239.37 is trading 94.7% below its estimated GF Value™ of ₹4,504.88.
GuruFocus considers Sun Pharma Advanced Research Co to be Possible Value Trap.
Key valuation signals for NSE:SPARC:
PB Ratio: 5.80 (82% below median its 10-year median of 32.34)
GF Value™: ₹4,504.88 vs. price of ₹239.37 (94.7% below fair value)
Industry Position: 203.7% above the Drug Manufacturers median (#780 of 921)
No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sun Pharma Advanced Research Co Business Description
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
61GF Score
Get the complete analysis for NSE:SPARC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SPARC has been successfully added to your 
